ECSP13012399A - A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE - Google Patents

A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE

Info

Publication number
ECSP13012399A
ECSP13012399A ECSP13012399A ECSP13012399A EC SP13012399 A ECSP13012399 A EC SP13012399A EC SP13012399 A ECSP13012399 A EC SP13012399A EC SP13012399 A ECSP13012399 A EC SP13012399A
Authority
EC
Ecuador
Prior art keywords
csf
conjugate
stimulating factor
new
granulocit
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Dmitriy Morozov
Elena Leonidovna Morozova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012399(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of ECSP13012399A publication Critical patent/ECSP13012399A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona a farmacéuticos y medicina, específicamente, a un nuevo conjugado fisiológicamente de granulocita colonia estimulante factor (G-CSF) con la fórmula general: Donde:n - intergers de 681 a 1 000;m - interger ? 4;NªH-G-CSF - Natural o recombinante polipéptido, teniendo actividad de G-CSFLa invención también está relacionada a medicinas conteniendo el conjugado reclamado de fórmula (1), composiciones farmacéuticas, el uso de conjugado de fórmula (1) para drogas y medicinas con granulocita colonia estimulante factor como un ingrediente activo, se aproxima a prevenir y/o tratar la neutropenia, el contenedor que contiene la composición farmacéutica.The present invention relates to pharmacists and medicine, specifically, to a new physiologically conjugated granulocyte colony stimulating factor (G-CSF) with the general formula: Where: n - intergers from 681 to 1 000; m - interger? 4; NªH-G-CSF - Natural or recombinant polypeptide, having G-CSF activity The invention is also related to medicines containing the claimed conjugate of formula (1), pharmaceutical compositions, the use of conjugate of formula (1) for drugs and Medicines with granulocyte colony stimulating factor as an active ingredient, comes close to preventing and / or treating neutropenia, the container that contains the pharmaceutical composition.

ECSP13012399 2010-08-13 2013-01-18 A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE ECSP13012399A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
ECSP13012399A true ECSP13012399A (en) 2013-05-31

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012399 ECSP13012399A (en) 2010-08-13 2013-01-18 A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE

Country Status (18)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
PH (1) PH12012502426A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
EP2858636B1 (en) 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
KR20160113302A (en) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 Compositions and methods for treating neutropenia
ES3002087T3 (en) 2014-07-14 2025-03-06 Gennova Biopharmaceuticals Ltd A novel process for purification of rhu-gcsf
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
NZ791835A (en) * 2020-03-17 2025-10-31 Drugrecure Aps Liquid formulation of gm-csf for inhalation
JP2023518412A (en) * 2020-03-20 2023-05-01 アムジェン インコーポレイテッド Determination of the free N-terminus of pegfilgrastim using acid protease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2989002B2 (en) * 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
MX2008009125A (en) * 2006-01-18 2008-10-23 Qps Llc Pharmaceutical compositions with enhanced stability.
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc MODIFIED RIBONUCLEASES

Also Published As

Publication number Publication date
CO6670557A2 (en) 2013-05-15
CU24139B1 (en) 2015-12-23
KR101549457B1 (en) 2015-09-02
CN103140499A (en) 2013-06-05
RU2446173C1 (en) 2012-03-27
SG187572A1 (en) 2013-03-28
DOP2013000003A (en) 2013-07-31
CL2013000400A1 (en) 2013-07-26
EA201101035A1 (en) 2012-02-28
PE20131085A1 (en) 2013-10-10
PH12012502426A1 (en) 2021-06-02
MY160732A (en) 2017-03-15
CN103140499B (en) 2014-12-17
RS20130094A1 (en) 2013-08-30
WO2012021088A1 (en) 2012-02-16
EA019043B1 (en) 2013-12-30
NI201300007A (en) 2014-05-26
CR20130020A (en) 2013-02-20
MA34525B1 (en) 2013-09-02
CU20130012A7 (en) 2013-04-19
KR20130043167A (en) 2013-04-29

Similar Documents

Publication Publication Date Title
ECSP13012399A (en) A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EA201390409A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL-SOLUBLE COATING
NZ704011A (en) Abuse deterrent pharmaceutical compositions for controlled release
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
EA201270034A1 (en) SOLID TABLETS OF MEDICINES FOR IMPLANTABLE DEVICES FOR DELIVERY OF MEDICINES
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
MX345238B (en) (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases.
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
CO5640037A2 (en) DERIVATIVES OF QUINAZOLINE FOR THE TREATMENT OF CANCER
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
PH12014502619A1 (en) Novel dosage and formulation
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
BR112013006651A2 (en) composition and cocrystal of l-proline aprepitant
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
BR112015027247A2 (en) inhalable pharmaceutical compositions and inhaler devices containing the same
MX2015010594A (en) Lipobalanced long chain testosterone esters for oral delivery.
PH12012501261A1 (en) Piperazines as antimalarial agents
MX373378B (en) A WATER-SOLUBLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE THERAPEUTIC ACTIVE SUBSTANCE WITH HYDROPHOBIC CHARACTERISTICS AND AT LEAST ONE COMPOUND SELECTED FROM SIALOGLYCOSPHINGOLIPIDS, GLYCOSPHINGOLIPIDS OR A MIXTURE OF SIALOGLYCOSPHINGOLIPIDS AND GLYCOSPHINGOLIPIDS.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
WO2015027669A3 (en) Phenyl-substituted compound, pharmaceutical composition and uses thereof
UA97076C2 (en) Anti-inflammatory ointment based on sulfanilamide